ED Coding & Reimbursement Alert - 2011 Issue 43
Q2043: New HCPCS Code Will Bring You $32,000 x 3 -- If You Bill It Properly
Subscribe or sign in to view the full article.
Article Overview
This article covers a 2012 HCPCS update related to a prostate cancer therapy for metastatic castrate resistant disease. It is written for coders, billers, and urology practices that need to understand the general reporting context, the associated diagnosis-code support, and the broader reimbursement implications discussed in the article.
Why This Topic Matters
Understanding this update helps practices identify when the article applies to a prostate cancer treatment scenario and why proper claim support matters for payment processing. It is relevant to teams responsible for coding, billing, and reimbursement compliance in urology and oncology settings.
Article Sections
-
Get to Know the Procedure
Introduces the therapy, the clinical context in which it is used, and the overall treatment workflow described in the article.
-
Report the New Code 3 Times For Full Treatment
Discusses the 2012 HCPCS update, the treatment cycle, and the reporting context associated with the new code.
-
Support Claim With Proper Diagnostic Codes
Outlines the diagnosis-code support discussed for claims submitted with the therapy and highlights the related metastatic disease categories.
What You Will Learn
- The general purpose of the 2012 HCPCS update described in the article
- How the article frames the treatment workflow and claim-support context
- What kinds of diagnosis-code support are discussed for this prostate cancer therapy
- Why this update is relevant to urology and oncology billing workflows
Who Should Read This
- Urology coders
- Medical billers
- Revenue cycle staff
- Oncology billing teams
- Physician practice administrators
Codes Discussed
Subscribe or sign in to view the full article.


Quick, Current, Complete - www.findacode.com